Fisher Funds Management LTD Acquires New Shares in Organon & Co. (NYSE:OGN)

Fisher Funds Management LTD bought a new position in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 126,716 shares of the company’s stock, valued at approximately $1,897,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Blue Trust Inc. increased its position in Organon & Co. by 217.5% during the 3rd quarter. Blue Trust Inc. now owns 3,661 shares of the company’s stock worth $76,000 after purchasing an additional 2,508 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Organon & Co. by 6.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 261,191 shares of the company’s stock worth $4,997,000 after buying an additional 15,187 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Organon & Co. by 137.4% during the third quarter. Sequoia Financial Advisors LLC now owns 28,776 shares of the company’s stock worth $550,000 after buying an additional 16,657 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Organon & Co. by 1,851.8% in the 3rd quarter. International Assets Investment Management LLC now owns 19,089 shares of the company’s stock valued at $365,000 after acquiring an additional 18,111 shares during the last quarter. Finally, Abich Financial Wealth Management LLC boosted its holdings in shares of Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after acquiring an additional 2,315 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. Finally, Barclays dropped their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Trading Down 1.4 %

NYSE OGN opened at $15.47 on Monday. The firm has a market capitalization of $3.98 billion, a PE ratio of 4.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The business’s 50-day moving average price is $15.36 and its two-hundred day moving average price is $17.26. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.